Weight Loss Supplements: Benefits, Evidence, and Safety

Overview

More than two-thirds of adults and nearly one-third of children and adolescents in the United States are overweight or have obesity [1][2]. Approximately 45% of Americans who are overweight and 67% of those with obesity are actively trying to lose weight [3]. About 15% of U.S. adults have used a weight-loss dietary supplement at some point, with more women reporting use (21%) than men (10%) [8]. Americans spend approximately $2.1 billion per year on weight-loss supplements in pill form alone [9].

Weight-loss dietary supplements contain a wide variety of ingredients -- botanicals, dietary fiber, caffeine, minerals, amino acids, and proprietary blends -- and come in capsules, tablets, liquids, powders, and bars [11]. Manufacturers market these products with claims that they reduce macronutrient absorption, suppress appetite, decrease body fat, increase metabolism, or enhance thermogenesis. Some products contain more than 90 ingredients [11].

The evidence supporting most weight-loss supplement ingredients is weak to moderate at best. The U.S. Government Accountability Office has concluded that "little is known about whether weight loss supplements are effective, but some supplements have been associated with the potential for physical harm" [12]. Health experts agree that lifestyle modification -- a healthy dietary pattern, reduced caloric intake, and regular physical activity -- remains the foundation for sustainable weight loss [4][5][6][7]. Dietary supplements, even when they show statistically significant effects in trials, typically produce only modest additional weight loss (often 1-2 kg over several months), and many carry safety concerns that must be weighed against these small benefits [6][14].

This article reviews the evidence for the most commonly used weight-loss supplement ingredients, covering efficacy data from clinical trials, recommended dosing where evidence exists, safety profiles, and drug interactions. The goal is to provide a comprehensive, evidence-based assessment so that readers can make informed decisions in consultation with their healthcare provider.

Table of Contents

• Overview
• Regulation of Weight-Loss Supplements
• Evidence for Benefits by Ingredient
• Summary of Evidence
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary and Lifestyle Approaches
• References

Regulation of Weight-Loss Supplements

The U.S. Food and Drug Administration (FDA) regulates dietary supplements, including those promoted for weight loss, but the regulatory framework differs substantially from that applied to prescription and over-the-counter medications [13]. Key distinctions:

• No premarket approval: Unlike drugs, dietary supplements do not require FDA review or approval before they are sold. Manufacturers are responsible for determining that their products are safe and that label claims are truthful [13].
• Post-market enforcement: If FDA identifies a supplement as unsafe, it may take enforcement action to remove the product from the market or request a voluntary recall.
• No pharmaceutical ingredients permitted: FDA does not permit dietary supplements to contain prescription drug ingredients. However, adulteration remains a significant problem (see Safety section below).
• Claims limitations: Manufacturers may not promote supplements to diagnose, treat, cure, or prevent any disease. FDA and the Federal Trade Commission (FTC) can take regulatory action against unsubstantiated weight-loss claims [13].

Between January 2004 and December 2012, 237 dietary supplements were subject to Class I recall by FDA (indicating a reasonable probability of serious adverse health consequences), and 27% of these were weight-loss products [238]. In most cases, the recall was due to undeclared pharmaceutical ingredients, most commonly sibutramine -- a weight-loss drug withdrawn from the U.S. market in 2010 due to cardiovascular safety concerns [237]. FDA maintains a public database of tainted weight-loss products.

Evidence for Benefits by Ingredient

Caffeine (Including Guarana, Kola Nut, Yerba Mate, and Other Herbal Sources)

Caffeine is a methylxanthine stimulant found in coffee, tea, guarana (Paullinia cupana), kola nut (Cola nitida), yerba mate (Ilex paraguariensis), and cacao [42][43]. It is one of the most common ingredients in weight-loss supplements, sometimes listed only as an herbal ingredient without specifying the caffeine content [41]. Caffeine has a half-life of about 6 hours; blood levels increase within 15-45 minutes of consumption and peak at approximately 60 minutes [44]. Caffeine increases thermogenesis in a linear, dose-dependent manner: a 100 mg dose increases energy expenditure by approximately 9.2 kcal/hr above placebo, with effects lasting 3 hours or more [45]. Caffeine also increases fat oxidation through sympathetic nervous system activation and promotes fluid loss [41][45]. However, habitual use leads to tolerance and diminished thermogenic effects [41][43].

Clinical evidence:

A meta-analysis of 6 RCTs (n=98) found that caffeine alone or in combination with catechins significantly increases energy expenditure in a dose-dependent fashion compared with placebo [157]. Caffeine combined with catechins also significantly increases fat oxidation, but caffeine alone does not.

In one RCT, 167 participants with overweight or obesity (BMI 25-40) received a supplement containing kola nut (192 mg/day caffeine) and ma huang (90 mg/day ephedrine) or placebo for 6 months [46]. Those in the treatment group lost significantly more weight (mean 5.3 kg) than placebo (2.6 kg) and had greater body fat reduction. However, this combination included the now-banned ingredient ephedra.

A Japanese RCT in 75 healthy adults with overweight (BMI 24-30) compared placebo to four formulations of caffeine (0, 25, 50, or 75 mg) plus 500 mg glucosyl hesperidin (G-hesperidin) daily for 12 weeks [47]. The 75 mg caffeine plus G-hesperidin group significantly reduced BMI by 0.56 versus 0.02 for placebo, and the 50-75 mg caffeine formulations significantly reduced abdominal fat. G-hesperidin alone or with only 25 mg caffeine did not produce significant effects, suggesting the higher caffeine doses were responsible.

In another RCT, 47 adults with overweight (BMI 26-30) were randomized to a combination product containing 336 mg yerba mate, 285 mg guarana, and 108 mg damiana or placebo before each meal for 45 days [48]. The herbal group lost 5.1 kg compared to 0.3 kg for placebo.

Observational data: A 12-year prospective study following 18,417 men and 39,740 women from the Nurses' Health Study and Health Professionals Follow-Up Study found that men who increased caffeine intake gained 0.43 kg less than those who decreased intake; for women, the difference was 0.35 kg [49]. A cross-sectional study of German adults found that successful weight-loss maintainers consumed significantly more caffeinated beverages (3.83 cups/day) than the general population (3.35 cups/day) [50].

Safety: For healthy adults, FDA and the European Food Safety Authority (EFSA) state that up to 400 mg/day caffeine does not pose safety concerns [51][52]. The American Medical Association recommends a limit of 500 mg/day [53]. For reference, an 8-ounce cup of brewed coffee contains approximately 85-100 mg caffeine. EFSA has not set a safe level for children; the American Academy of Pediatrics discourages caffeine consumption in children and adolescents [51-54].

Caffeine can cause sleep disturbances, nervousness, jitteriness, and shakiness. It becomes toxic at approximately 15 mg/kg body weight (about 1,000 mg for a 68 kg adult), causing nausea, vomiting, tachycardia, seizures, and cerebral edema [42]. Doses above 150 mg/kg (approximately 10,000 mg) can be fatal. Chronic use in large amounts can produce tolerance, habituation, and psychological dependence. An EFSA expert panel (2015) determined that single doses up to 200 mg (about 3 mg/kg) do not raise safety concerns, with a daily limit of 200 mg for pregnant or breastfeeding women [52]. A study of four popular stimulant supplements found all caused significant increases in blood pressure (8-12 mmHg systolic) and changes in heart rate or rhythm in healthy young men; common side effects included nausea, insomnia, and increased anxiety (Foster, Clin Pharmacol Ther 2013). According to a California Poison Control System analysis, 47% of calls reporting adverse effects from dietary supplements involved caffeine-containing products [55].

Green Tea and Green Tea Extract (Camellia sinensis)

Green tea contains caffeine (approximately 45 mg per cup) and catechins, primarily epigallocatechin gallate (EGCG). A typical brewed cup contains 240-320 mg catechins [156]. Green tea and its extracts are proposed to reduce body weight by increasing energy expenditure and fat oxidation, reducing lipogenesis, decreasing fat absorption, and decreasing carbohydrate digestion [41][157-161]. Research suggests that catechins and caffeine act synergistically -- EGCG alone does not increase resting metabolic rate, fat oxidation, or the thermic effect of feeding [162][163].

Clinical evidence:

A 2012 Cochrane Review analyzed 14 RCTs (n=1,562) of green tea preparations in participants with overweight or obesity [164]. Trials lasted 12-13 weeks with catechin doses of 141-1,207 mg; 10 of 14 trials included caffeine. Green tea reduced body weight by 0.95 kg more than placebo. However, when the authors restricted analysis to the 6 studies conducted outside Japan (with less heterogeneous methodologies), the effect was no longer statistically significant.

A systematic review and meta-analysis of 15 RCTs found that green tea catechins (576-690 mg/day) combined with caffeine (39-83 mg/day) for a median of 12 weeks modestly reduced body weight by 1.38 kg and waist circumference by 1.93 cm compared with caffeine alone [165]. Two studies examining catechins alone found no effect on body weight.

A meta-analysis of 11 RCTs found that EGCG combined with caffeine for 12-13 weeks produced a mean loss (or prevented a gain) of 1.31 kg compared with controls [167]. A 12-month trial of decaffeinated green tea extract (1,315 mg/day total catechins) had no overall effect on body weight, BMI, or waist circumference in 121 postmenopausal women with overweight or obesity [166].

In 2010, EFSA concluded that "a cause and effect relationship has not been established between the consumption of catechins (including EGCG) from green tea and contribution to the maintenance or achievement of a normal body weight" [168].

Studies suggest green tea extract providing 270-432 mg EGCG/day might help reduce weight in moderately obese patients, but the effects are small and unlikely to be clinically relevant.

Safety: No adverse effects from green tea consumed as a beverage [156]. Green tea extract can cause constipation, abdominal discomfort, nausea, and increased blood pressure [164]. There is increasing evidence that green tea extract can cause liver damage [170]. An analysis of 1,021 postmenopausal women found that those consuming green tea extract (1,315 mg catechins including 843 mg EGCG) daily for 12 months had significantly increased liver enzymes compared with placebo, and some developed moderate or more severe liver function abnormalities [170]. At least 50 case reports of liver damage associated with green tea extracts (primarily ethanolic extracts) have been published since 2006 [43][172]. The U.S. Pharmacopeia reviewed 34 cases and concluded green tea products "probably" caused 7 cases and "possibly" caused 27 cases [173]. USP advises taking green tea extract with food to minimize risk. Toxicology studies in rodents show green tea extract causes nonneoplastic lesions in the nose, liver, and bone marrow, and high-dose catechins cause liver toxicity [169].

Garcinia Cambogia (Hydroxycitric Acid / HCA)

Garcinia cambogia is a fruit-bearing tree native to Asia, Africa, and the Polynesian islands [128]. Its rind contains hydroxycitric acid (HCA), which is proposed to inhibit lipogenesis (via inhibition of ATP citrate lyase), increase hepatic glycogen synthesis, suppress food intake, and reduce weight gain [6][15][109][128][129]. HCA represents up to 16% of the dried fruit weight and typically 50% of standardized extracts.

Clinical evidence:

In an RCT of 89 mildly overweight women (mean BMI 28.6), those receiving 2.4 g/day Garcinia cambogia (1,200 mg HCA) before meals for 12 weeks lost significantly more weight (3.7 kg) than placebo (2.4 kg), though the supplement did not alter appetite or satiety [131].

In a larger RCT of 135 men and women with overweight (BMI 27-38) receiving 3,000 mg/day Garcinia cambogia (1,500 mg HCA) for 12 weeks on a high-fiber, low-energy diet, both groups lost weight but the between-group difference was not statistically significant [132]. HCA had no effect on body fat loss.

A 2011 meta-analysis of 12 RCTs (n=706) found that Garcinia cambogia (1,000-2,800 mg/day HCA) for 2-12 weeks reduced body weight by 0.88 kg versus placebo [130]. However, when only the two rigorously designed trials were considered, the effect was no longer statistically significant. The authors of a 2013 review reached similar conclusions, noting that efficacy "remains to be proven in larger-scale and longer-term clinical trials" [133].

The typical dose used in studies contains 500 mg of HCA taken three to four times daily.

Safety: Reported adverse effects are generally mild: headache, nausea, upper respiratory tract symptoms, and gastrointestinal symptoms [128][130][132]. Three case reports have linked Garcinia cambogia supplements to mania (possibly via serotonergic activity of HCA), with symptoms including grandiosity, irritability, pressured speech, and decreased need for sleep [134]. Ten cases of liver toxicity have been reported, including one death and two liver transplants, though most products also contained other botanical ingredients [43][135-137]. Long-term safety is unknown, as all clinical trials have been short.

Chromium

The trivalent form of chromium (chromium III) is an essential trace mineral that potentiates insulin action [98]. The Adequate Intake is 20-35 mcg/day for adults. Chromium picolinate is the most common supplemental form. It has been hypothesized that chromium increases lean muscle mass, promotes fat loss, reduces food intake, and decreases fat cravings [41][100][101].

Clinical evidence:

A 2013 Cochrane Review analyzed 9 RCTs (n=622) of chromium picolinate (200-1,000 mcg/day) for 8 weeks to 6 months in participants with overweight or obesity (BMI 25+) [100]. Six trials included exercise training. Chromium picolinate reduced body weight by 1.1 kg more than placebo, but the amount of weight loss did not correlate with dose. The authors described the effect as of "debatable clinical relevance" with overall low quality of evidence.

A systematic review and meta-analysis of 11 RCTs (n=866) found that 137-1,000 mcg/day chromium for 8-26 weeks reduced body weight by 0.5 kg and body fat by 0.46%, effects described as of "uncertain" clinical relevance [99]. An earlier meta-analysis of 12 trials reported similar findings [102].

Evidence suggests chromium can help some people control blood sugar levels, but its effects on weight loss and body composition are minimal.

Safety: Adverse effects include watery stools, headache, weakness, nausea, vomiting, constipation, vertigo, and urticaria [99][100]. The trivalent form is generally considered safe at 200 mcg/day or less; reports of toxicity have occurred at doses over 600 mcg. Chromium does not have an established UL because few serious adverse effects have been linked to dietary intakes [98]. Hexavalent chromium (chromium VI) is toxic and should not be found in supplements.

Dr Brad Stanfield's MicroVitamin includes 17.5 mcg of chromium in the glycinate form -- well within the Adequate Intake range of 20-35 mcg/day and designed to support normal trace mineral status rather than weight loss.

Conjugated Linoleic Acid (CLA)

CLA is a mixture of linoleic acid isomers (mainly c9,t11-CLA and t10,c12-CLA) found in dairy products and beef [109]. It is proposed to enhance weight loss by increasing lipolysis, reducing lipogenesis, and promoting apoptosis in adipose tissue [17][110].

Clinical evidence:

A double-blind trial in 180 volunteers with overweight (BMI 25-30) tested CLA as free fatty acid (3.6 g/day) or triacylglycerol (3.4 g/day) versus placebo for 1 year [109]. Body fat mass decreased by 6.9% with the free fatty acid form and 8.7% with the triacylglycerol form compared with placebo. The free fatty acid form also increased lean body mass.

A crossover trial found 6.4 g/day CLA for 16 weeks significantly reduced BMI and total body fat compared with safflower oil in 35 postmenopausal women with obesity and type 2 diabetes [112].

A 12-week RCT (n=63, BMI 24-35) found that 3.4 g/day CLA produced small but statistically significant reductions in weight (0.69 kg) and body fat (0.49 kg) versus baseline [113]. However, 3.2 g/day CLA combined with aerobic exercise for 8 weeks did not reduce body fat in 28 young women with obesity [114].

A systematic review and meta-analysis of 7 RCTs found that 2.4-6 g/day CLA for 6-12 months reduces body weight by 0.7 kg and body fat by 1.33 kg versus placebo [111]. The authors stated the "magnitude of these effects is small, and the clinical relevance is uncertain."

Safety: Most adverse effects are gastrointestinal: abdominal discomfort, constipation, diarrhea, loose stools, nausea, and dyspepsia [109][111][113]. Three case reports linked CLA to hepatitis, though products were not analyzed for contaminants [118-120]. CLA might decrease HDL cholesterol and increase lipoprotein(a) levels [109][110][116][121-124]. The t10,c12-CLA isomer has been reported to increase insulin resistance and glycemia in men with obesity and metabolic syndrome [110][124]. CLA might also increase markers of oxidative stress and decrease breastmilk fat levels [117].

Bitter Orange (Citrus aurantium) / Synephrine

Bitter orange extract from the fruit peel contains synephrine and other protoalkaloids that act as alpha-adrenergic agonists [25-28]. After the FDA ban on ephedra in 2004, bitter orange became a common "ephedra-free" replacement in weight-loss supplements [29]. Synephrine has some structural similarity to ephedrine but different pharmacological properties [27][30].

Clinical evidence:

In an RCT of 20 healthy adults with overweight (BMI >25), a product containing 975 mg bitter orange extract (6% synephrine), 528 mg caffeine, and 900 mg St. John's wort for 6 weeks during an exercise program reduced body fat percentage and fat mass more than placebo [31][32]. However, participants in all groups lost weight and the between-group difference in body weight was not clearly significant.

In 8 adults with overweight or obesity (BMI 25-40), an herbal supplement providing 18 mg synephrine/day plus 396 mg caffeine/day for 8 weeks significantly increased resting metabolic rate at baseline but this was not significant at 8 weeks. The treatment group actually gained weight (1.13 kg) versus placebo (0.09 kg) [33].

An RCT in 80 healthy resistance-trained men found that a supplement containing bitter orange (20 mg synephrine/day) with 284 mg caffeine for 8 weeks did not increase resting heart rate, blood pressure, or reported side effects compared with placebo [40].

A 2012 review of 23 small studies (n=360 total) concluded synephrine increases resting metabolic rate and energy expenditure [30]. A 2011 systematic review of four weight-loss trials concluded that evidence for bitter orange/synephrine is "contradictory and weak" [34].

Safety: Significant safety concerns exist. Reported adverse effects include chest pain, headache, anxiety, elevated heart rate, musculoskeletal complaints, ventricular fibrillation, ischemic stroke, myocardial infarction, and death [34][35]. However, many products contain multiple ingredients, making it difficult to isolate bitter orange's role. A single dose of 900 mg bitter orange (54 mg synephrine) significantly increased heart rate and blood pressure for up to 5 hours in 15 healthy adults [38]. Other compounds in the extract may contribute to cardiovascular effects (Hansen, Toxicol Appl Pharmacol 2012). Canada has approved up to 50 mg/day p-synephrine alone, or 40 mg/day when combined with up to 320 mg/day caffeine. Persons with hypertension, heart disease, or narrow-angle glaucoma should avoid bitter orange. Risks may be higher in products with boosted synephrine levels or when combined with other stimulants.

Carnitine (L-Carnitine)

L-carnitine is composed of the amino acids lysine and methionine and transports fatty acids into mitochondria for beta-oxidation [84][85]. It is naturally present in animal products (meat, fish, poultry, milk) and synthesized endogenously, so dietary intake is not essential.

Clinical evidence:

A clinical trial in 258 patients with uncontrolled type 2 diabetes found that 2 g/day L-carnitine plus orlistat (360 mg/day) for 1 year significantly increased weight loss compared with orlistat alone [86]. However, 2 g/day L-carnitine alone for 6 months did not affect weight in 94 adults with overweight and newly diagnosed type 2 diabetes [87].

A 2016 systematic review and meta-analysis of 9 trials (n=911) found that L-carnitine supplementation (1.8-4 g/day for 30-360 days) produced a mean additional weight loss of 1.33 kg versus placebo [85].

Safety: Well tolerated at doses up to 4 g/day [88-90]. Common adverse effects: nausea, vomiting, abdominal cramps, diarrhea, and fishy body odor. Rarer effects include muscle weakness in uremia patients and seizures in those with seizure disorders. Some research indicates intestinal bacteria metabolize carnitine to trimethylamine N-oxide (TMAO), which might increase cardiovascular disease risk [91]. This effect appears more pronounced in meat-eaters than vegans or vegetarians.

Glucomannan (Konjac Root Fiber)

Glucomannan is a water-soluble fiber from konjac root (Amorphophallus konjac) that can absorb up to 50 times its weight in water, creating a gel-like mass in the gut that promotes satiety and slows gastric emptying [16][138][139]. It may also reduce fat and protein absorption in the gut [16].

Clinical evidence:

In a small U.S. study, 20 women with obesity consumed 3 g/day glucomannan (1 g before each meal) or placebo for 8 weeks [141]. Glucomannan produced significantly greater weight loss (mean 2.5 kg) than placebo (mean gain of 0.7 kg).

However, 3.9 g/day glucomannan for 4 weeks in 63 healthy men did not significantly reduce body weight [142]. Eight weeks of 3.99 g/day glucomannan also failed to reduce body weight in 53 adults with overweight or obesity [143]. Two grams per day for 2 months had no significant effect on weight in 60 children with obesity [140].

A 2015 systematic review of 6 RCTs (n=293) concluded that 1.24-3.99 g/day glucomannan for up to 12 weeks does not significantly affect body weight [144][145]. A 2014 meta-analysis of 8 trials (n=301) reached the same conclusion [146]. An older meta-analysis of 14 studies found a small but statistically significant weight loss (0.79 kg more than placebo) over approximately 5 weeks [139].

Glucomannan appears to have beneficial effects on blood lipids and glucose levels [139], and most early studies suggest a short-term benefit at about 1 gram with each meal.

Safety: Generally well tolerated. Minor adverse effects include belching, bloating, loose stools, flatulence, diarrhea, constipation, and abdominal discomfort [139][143][144][146]. Tablet forms of glucomannan were associated with 7 cases of esophageal obstruction in Australia in 1984-1985 [99]; powdered and capsule forms have not been associated with this effect [147]. Must be taken with plenty of water to avoid getting stuck in the throat as it expands. May lower blood glucose levels and interact with diabetes medications [139][147].

Chitosan

Chitosan is a polysaccharide derived from the exoskeletons of crustaceans, promoted as a "fat blocker" that binds dietary fat in the digestive tract to prevent absorption [16][41]. It may also decrease cholesterol absorption [16].

Clinical evidence:

A small study (12 men, 12 women, BMI 20-36) found that 2.5 g/day chitosan slightly increased fecal fat excretion in men, but the amount of fat trapped would result in a loss of only 1 lb over approximately 7 months. Chitosan had no effect on fecal fat in women [92].

An RCT of 59 women with overweight or obesity (BMI 27-40) found that 3 g/day chitosan for 8 weeks produced a 1 kg weight loss versus a 1.5 kg gain in the placebo group [93]. Another 8-week study found chitosan (3 g/day) reduced body weight by about 2.5 kg compared with about 1 kg for placebo; adding ascorbic acid (2 g/day) led to an additional 1.5 kg reduction [94]. In contrast, a 28-day trial of 2 g/day chitosan in 34 adults with overweight failed to reduce body weight [95].

A Cochrane Review of 13 trials found chitosan reduced body weight by 1.7 kg versus placebo over 4 weeks to 6 months [96], but the authors noted most studies were of poor quality and results from high-quality trials indicate "minimal effects" that are "probably clinically insignificant."

Safety: Minor gastrointestinal effects including flatulence, bloating, nausea, constipation, indigestion, and heartburn [93][95][96]. People allergic to shellfish could theoretically be allergic to chitosan [97]. Chitosan may potentiate the anticoagulant effects of warfarin [239].

Forskolin (Coleus forskohlii)

Forskolin is a compound from the roots of Coleus forskohlii, proposed to promote weight loss by stimulating cyclic adenosine monophosphate (cAMP) production, activating lipase, and releasing fatty acids from adipose tissue [16][103][104].

Clinical evidence:

An RCT of 30 men with overweight (BMI 26+) found that 500 mg/day Coleus forskohlii extract (10% forskolin, Forslean by Sabinsa) for 12 weeks did not reduce body weight but did significantly decrease mean body fat by about 4% versus about 1% for placebo, and significantly increased lean body mass, bone mass, and free testosterone levels (Godard, Obes Res 2005) [104].

The same extract and dose in 19 women with overweight or obesity (BMI 25-35) for 12 weeks had no effect on body weight, appetite, caloric intake, or body composition, but did significantly reduce hunger (Henderson, J Int Soc Sports Nutr 2005) [106].

A third 12-week trial in 30 adults with overweight or obesity (BMI >25) on a hypocaloric diet found no reduction in body weight, though plasma insulin concentrations significantly decreased [107].

Dosing: Clinical studies have used 250 mg of extract standardized to 10% forskolin (25 mg forskolin) taken twice daily, based on the branded Forslean extract. Some products provide a 20% extract at 125 mg, delivering the same amount of forskolin.

Safety: In mice, Coleus forskohlii extract caused dose-dependent liver toxicity, but pure forskolin did not -- suggesting other plant compounds may be responsible [108]. In humans, forskolin may increase bowel movement frequency and cause loose stools [107]. Doses of 500 mg/day (10% forskolin) for 12 weeks have not produced serious adverse events [104][106][107]. Although no significant blood pressure changes were found in clinical studies, other evidence suggests forskolin may lower blood pressure or increase heart rate. People with low blood pressure, those on blood pressure medications, blood thinners (warfarin, clopidogrel), calcium channel blockers (nifedipine, diltiazem), or nitroglycerin should use forskolin only under physician supervision.

White Kidney Bean Extract (Phaseolus vulgaris) -- "Starch Blocker"

Phaseolus vulgaris extract inhibits alpha-amylase, interfering with starch breakdown and absorption. It may also suppress appetite [16][211-215].

Clinical evidence:

An Italian RCT in 60 mildly overweight women (mean BMI 26) found that 445 mg/day Phaseolus vulgaris extract (Phase 2 Starch Neutralizer) for 30 days produced significantly greater weight loss (2.93 kg) than placebo (0.35 kg), with greater reductions in fat mass and waist-hip-thigh circumference [216].

A U.S. trial in 39 adults with obesity (BMI 30-43) found that 3,000 mg/day Phase 2 for 8 weeks on a high-fiber/low-fat diet did not significantly improve weight loss versus placebo [212].

A 12-week RCT (n=123, BMI 25-35) found that 3,000 mg/day Phaseolus vulgaris (IQP-PV-101) on a mildly hypocaloric diet produced significantly more weight loss (2.91 kg) and fat loss (2.23 kg) versus placebo (0.92 kg and 0.65 kg, respectively) [217].

A 2011 review of 6 trials (n=247) concluded that 445-1,500 mg/day for 4-13 weeks significantly reduced body fat (1.86 kg vs. placebo) but did not significantly affect overall weight [211]. The authors noted poor trial quality. Extracts should be standardized to provide a defined amount of alpha-amylase inhibiting units (AAIU) per gram, such as 3,000 AAIU (Onakpoya, Br J Nutr 2011).

Safety: Minor adverse effects: headaches, soft stools, flatulence, and constipation [211]. No serious adverse effects reported, but no trials have lasted longer than 13 weeks.

Probiotics

Gut microbiota play a role in nutrient and energy extraction from food. Research in mice suggests microbiota affect energy expenditure and storage [189]. Probiotics are proposed as a means to manipulate gut flora to prevent or treat obesity [187][188]. Probiotic genera include Lactobacillus, Streptococcus, and Bifidobacterium, which have widely varying effects in the body [188][189].

Clinical evidence:

A 12-week RCT (n=210 healthy adults with high visceral fat) found that Lactobacillus gasseri SBT2055 in fermented milk significantly reduced visceral fat area (8.2-8.5%), BMI, waist and hip circumference, and body fat mass compared with control [191].

In 125 adults with obesity, 24 weeks of Lactobacillus rhamnosus CGMCC1.3724 plus energy restriction did not significantly affect weight versus placebo overall, but among 77 female participants, the probiotic significantly reduced body weight at 12 weeks (1.8 kg) and 24 weeks (2.6 kg) versus placebo [192].

A 2017 systematic review of 14 trials (n=1,067) in individuals with overweight or obesity found probiotics (mostly Lactobacillus, various doses, 3 weeks to 6 months) significantly decreased body weight and/or body fat in 9 trials, had no effect in 3, and increased body weight in 2 [193].

A meta-analysis of 15 RCTs (n=957) found that probiotics for 3-12 weeks produced larger reductions in body weight (0.6 kg), BMI (0.27), and fat percentage (0.6%) than placebo -- effects described as small and of "questionable clinical significance" [194].

The most recent meta-analysis (19 RCTs, n=1,412) found probiotics or synbiotics reduced waist circumference by 0.82 cm but had no effect on body weight or BMI [195]. Another meta-analysis found an average loss of 0.54 kg in 881 adults across 14 trials, a gain of 0.20 kg in 726 children across 5 trials, and no significant effect in 1,154 infants across 12 trials [196].

Safety: Generally safe for healthy individuals. Side effects are mostly gastrointestinal (gas). In rare cases involving severely ill or immunocompromised individuals, probiotics have been linked to bacteremia, fungemia, or serious infections [198][199]. The World Gastroenterology Organisation advises restricting probiotic use to strains and indications with proven efficacy in immunocompromised populations [197].

7-Keto DHEA

7-keto DHEA (7-keto dehydroepiandrosterone) is a metabolite of DHEA that, unlike DHEA itself, does not convert to androgen or estrogen hormones [CL]. It is proposed to increase resting metabolic rate in overweight people on calorie-restricted diets.

Clinical evidence:

A dose of 100 mg twice daily was effective for weight loss in overweight or obese subjects who exercised on a reduced-calorie diet; 7-keto DHEA subjects lost more weight than placebo (Kaiman, Cur Ther Res 2000). Similar results were found using 7-keto DHEA in combination with other ingredients including L-tyrosine, asparagus root extract, choline bitartrate, inositol, copper gluconate, manganese, and potassium iodide (Zenk, Cur Ther Res 2002). A study demonstrated that 7-keto DHEA increases resting metabolic rate in obese people on a calorie-restricted diet (Zenk, J Nutr Biochem 2007).

However, these are short-term studies (1-8 weeks), small in size, and more research is needed.

Safety: Not well studied in humans. Used safely at up to 200 mg/day with no serious side effects in limited studies of 1-8 weeks duration. One subject experienced decreased hemoglobin and hematocrit. Treatment may decrease diastolic blood pressure and thyroxine levels. Does not significantly affect sex hormone levels (Davidson, Clin Invest Med 2000). May increase triiodothyronine (T3) levels (Kaiman, Cur Ther Res 2000).

African Mango (Irvingia gabonensis)

The seed kernel extract of Irvingia gabonensis is proposed to inhibit adipogenesis and reduce leptin levels [17][18].

Clinical evidence:

An RCT in Cameroon randomized 102 adults with overweight or obesity (BMI >25) to 300 mg/day IGOB131 (a proprietary extract, 150 mg 30-60 minutes before lunch and dinner) or placebo for 10 weeks [18]. Those receiving the extract had significantly lower body weight, body fat, and waist circumference at trial end.

A 2013 systematic review of 3 trials reported that the extract causes statistically significant reductions in body weight and waist circumference [19]. However, the authors noted that trials used different methodologies, small samples, short durations, varying doses (300-3,150 mg/day), and were all conducted by the same research group. Additional independent trials are needed.

Safety: Appears well tolerated. No adverse effects in rats at doses up to 2,500 mg/kg/day [20]. Mild human adverse effects: headache, difficulty sleeping, flatulence, and gas [19]. One case of renal failure was associated with African mango in a patient with pre-existing chronic kidney disease [21].

Raspberry Ketone

Raspberry ketone is the primary aroma compound in red raspberries. Found in very small amounts in the fruit (1 pound of raspberries provides about 1 mg of ketone); the ingredient in supplements is often synthetic due to lower cost. Animal and in vitro studies suggest it may reduce food intake, prevent weight gain, and promote fat breakdown [16][204][205]. Despite popularization on television as an effective fat burner, human evidence is essentially nonexistent.

Clinical evidence:

No studies of raspberry ketone alone exist in humans. In mice fed a high-fat diet, raspberry ketone prevented weight gain and promoted fat breakdown (Morimoto, Life Sci 2005). Fat breakdown was also shown in cell experiments (Park, Planta Med 2010).

The only human RCT (n=70, BMI >27) used a multi-ingredient product (METABO) containing 2,000 mg of a proprietary blend of raspberry ketone, caffeine, bitter orange, ginger, garlic, cayenne, L-theanine, and pepper extract along with B-vitamins and chromium [206]. After 8 weeks with calorie restriction (500 kcal/day deficit) and exercise (60 minutes, 3 days/week), METABO produced greater weight loss (1.9 kg vs. 0.4 kg). However, 25 of 70 participants dropped out, no intention-to-treat analysis was performed, and the effects of raspberry ketone alone cannot be determined.

Safety: Safe as a food additive at trace levels. No safety studies at supplement doses of 100 mg or more per day. Due to lack of information about metabolic and other effects, people with pre-existing conditions (diabetes, high cholesterol, high blood pressure) should be monitored by a healthcare professional when using raspberry ketone.

Calcium

Calcium supplementation has been proposed to increase lipolysis, decrease fat accumulation, and reduce fat absorption [56-61]. Several mechanisms have been suggested, including reduced parathyroid hormone and active vitamin D leading to decreased intracellular calcium in fat cells and increased fat breakdown [59].

Clinical evidence:

A 2014 crossover trial in 15 healthy men found that high-calcium diets (1,700 mg/day from dairy) increased fecal fat excretion compared with a 500 mg/day control [68]. However, clinical trials of calcium supplements on body weight have been largely negative.

Supplementation with 1,500 mg/day calcium carbonate for 2 years in 340 adults with overweight or obesity (BMI 25+) had no clinically significant effect on weight [69].

A 2009 AHRQ evidence report concluded that clinical trial results do not support an effect of calcium supplementation on weight [70]. A 2015 meta-analysis of 41 RCTs found no benefit of calcium supplementation or increased dairy consumption for body weight or body fat [73]. A 2016 meta-analysis of 33 trials found no overall effect, although subgroup analyses showed some benefit in children, adolescents, adult men, premenopausal women, women over 60, and people with normal BMI [74].

Increased calcium from dairy products (but not supplements) is associated with greater weight loss when dieting, possibly due to additional bioactive components in dairy that modulate appetite-regulating hormones [60][61][64-67].

Safety: Safe at recommended intakes (1,000-1,200 mg/day for adults). The UL is 2,500 mg/day for ages 19-50 and 2,000 mg for adults 51+ [56]. High intake can cause constipation and may interfere with iron and zinc absorption. High intakes from supplements (not food) have been associated with increased kidney stone risk [56][75-77].

Vitamin D

Observational studies associate greater body weight with lower vitamin D status, and individuals with obesity frequently have deficient vitamin D levels [207]. This appears to be because subcutaneous fat sequesters vitamin D rather than because deficiency causes obesity [208].

Clinical evidence:

A systematic review of 15 weight-loss intervention studies (using caloric restriction and/or exercise) found that people who lost weight had greater increases in serum vitamin D, likely due to release of stored vitamin D from body fat [208].

In one study, 400 IU/day vitamin D plus 1,000 mg/day calcium slightly reduced weight gain versus placebo in postmenopausal women, especially those with baseline calcium intake below 1,200 mg/day [209].

A meta-analysis of 12 vitamin D supplementation trials found that without calorie restriction, vitamin D supplements did not affect body weight or fat mass versus placebo [210]. Overall, the available research suggests that consuming higher amounts of vitamin D or taking vitamin D supplements does not promote weight loss.

Safety: Safe at recommended intakes (600-800 IU/day for adults). Toxic at very high intakes. UL: 4,000 IU/day for adults and children 9+ [56]. Toxicity symptoms: anorexia, weight loss, polyuria, heart arrhythmias, and hypercalcemia leading to vascular and tissue calcification.

Capsaicin and Capsaicinoids

Capsaicinoids from chili peppers are proposed to increase energy expenditure, lipid oxidation, and satiety while reducing appetite and energy intake [78-82]. Capsaicin is the most abundant and well-studied capsaicinoid [78]. Some research suggests capsaicin increases satiety by inducing gastrointestinal distress rather than by releasing satiety hormones [82].

Clinical evidence:

A meta-analysis of 8 RCTs (n=191, normal weight to moderately overweight) found that capsaicinoids (0.2-33 mg/day via chili powder, chili foods, or chili capsules) significantly reduced energy intake by 74 kcal per meal; at least 2 mg appears needed [78]. However, body weight was not assessed.

A 2017 RCT in 77 adults with overweight compared 2 mg/day and 4 mg/day capsaicinoids for 12 weeks [83]. The 4 mg/day group reported 252 fewer calories per day than placebo and 140 fewer than the 2 mg/day group, but this did not significantly affect body weight at 6 or 12 weeks.

Safety: 4 mg/day can cause gastrointestinal distress [83]. May increase serum insulin and reduce HDL cholesterol. Otherwise appears safe. Research is underway to reduce pungency while retaining biological effects [81].

Pyruvate

Pyruvate is a three-carbon compound generated through glycolysis, proposed to enhance lipolysis and energy expenditure [6][200-202].

Clinical evidence:

An RCT (n=26, BMI 25+) found 6 g/day pyruvate for 6 weeks with exercise and a 2,000 kcal/day diet produced significant decreases in body weight (1.2 kg), body fat, and percent body fat versus baseline [200]. A study of 14 women with obesity found that 30 g/day pyruvate produced greater weight and fat loss over 21 days when isoenergetically substituted for glucose [203]. However, an RCT in 23 women with overweight found 5 g/day calcium pyruvate for 30 days did not affect any body composition measures [202]. Original research used 20-30 g/day; more recent studies suggest 3-5 g/day may have an effect.

A systematic review of 6 RCTs (n=203) concluded pyruvate (5-30 g/day for 3-6 weeks) reduces body weight by 0.72 kg and body fat by 0.54 kg versus placebo, though all trials had weak methodological quality [201].

Safety: Gas, bloating, diarrhea, and borborygmus at doses up to 30 g/day for 6 weeks. No serious adverse effects. Large doses (over 5 g/day) may cause abdominal discomfort. May increase LDL and decrease HDL cholesterol [201][202].

Caralluma fimbriata

An extract from a cactus plant promoted as an appetite suppressant.

Clinical evidence:

One 2-month RCT found 1 g/day suppressed appetite and reduced waist circumference, but did not significantly decrease body weight or body fat (Kuriyan, Appetite 2008). No other clinical trials available.

Safety: No long-term safety studies.

Fucoxanthin

A carotenoid from brown seaweed proposed to increase resting energy expenditure and fatty acid oxidation [125][126].

Clinical evidence:

One 16-week RCT studied Xanthigen (2.4 mg fucoxanthin + 300 mg pomegranate seed oil, 3 times daily before meals) in 110 premenopausal women with obesity on an 1,800 kcal/day diet [127]. Those with nonalcoholic fatty liver disease lost 6.9 kg versus 1.4 kg for placebo; those without NAFLD lost 6.3 kg versus 1.4 kg. However, this is the only human trial, and the role of fucoxanthin versus pomegranate oil alone cannot be separated.

Safety: Not thoroughly evaluated. No adverse effects reported in the single trial [127].

Hoodia (Hoodia gordonii)

A succulent plant from the Kalahari Desert, traditionally used by the San people as an appetite suppressant during long hunts. The proposed active ingredient is a glycoside called P57 [181].

Clinical evidence:

An RCT of 49 healthy women (mean BMI 25) found that 2,220 mg/day Hoodia gordonii extract for 15 days had no significant effect on energy intake or body weight versus placebo [184].

Safety: Significant increases in heart rate and blood pressure were reported [184]. Also raised bilirubin and alkaline phosphatase levels. Side effects include headache, dizziness, nausea, vomiting, and skin sensations. Past analyses found that only 30-60% of hoodia products contained adequate amounts of hoodia [186].

Yohimbe (Pausinystalia yohimbe)

Yohimbe bark contains yohimbine, an alpha-2 receptor antagonist with hyperadrenergic effects [218][219]. It is primarily used as a traditional remedy for sexual dysfunction in men but is also promoted for weight loss and bodybuilding.

Clinical evidence:

A small trial in 20 women with obesity (mean BMI 40-43) found 5 mg yohimbine four times daily on a 1,000 kcal/day diet for 3 weeks produced greater weight loss (3.55 kg) than placebo (2.21 kg) [220]. However, high-dose yohimbine (peak 43 mg/day) for 6 months had no effect on body weight or body fat in 47 overweight men [221]. Reviews have concluded there is no conclusive evidence yohimbe affects body weight [218][219].

Safety: Yohimbe can be dangerous. Doses of 20-40 mg yohimbine can increase blood pressure; doses of 200 mg or higher can cause headaches, hypertension, anxiety, agitation, tachycardia, myocardial infarction, cardiac failure, and death [43][177][218][219][222]. Between 2000 and 2012, yohimbe supplements accounted for 1,818 reports to U.S. poison control centers, with 30% deemed moderate or major adverse effects, 3.2% requiring critical care admission, and one death [223]. An analysis of 49 supplements found only 22% listed yohimbine quantity on the label, and actual content ranged from 23% to 147% of labeled amounts [224]. Yohimbe should only be used under medical supervision [225].

Guar Gum

A soluble fiber from the Indian cluster bean (Cyamopsis tetragonolobus) that absorbs water and creates a bulking effect in the gut, delaying gastric emptying and increasing satiety [16][174].

Clinical evidence:

A review concluded that 2-5 g guar gum increases satiety and reduces snacking frequency [175]. However, a meta-analysis of 20 RCTs (11 pooled, n=203) found guar gum (9-30 g/day for 3 weeks to 6 months) had no significant effect on weight versus placebo [174]. A study of 44 adults with type 2 diabetes found 10 g/day for 6 weeks reduced waist circumference but not body weight [176]. The meta-analysis authors concluded that guar gum is not effective for body weight reduction.

Safety: Gastrointestinal effects: abdominal pain, flatulence, diarrhea, nausea, and cramps [174][176][177]. Severe esophageal and small-bowel obstruction reported with an older product no longer available [178][179]. The meta-analysis authors concluded the risks outweigh the benefits [174].

Green Coffee Bean Extract

Green (unroasted) coffee beans contain higher levels of chlorogenic acid than roasted beans. Chlorogenic acid may inhibit fat accumulation and modulate glucose metabolism [148-151].

Clinical evidence:

A meta-analysis of 3 small trials found green coffee bean extract (180-200 mg/day for 4-12 weeks) produced a 2.47 kg mean weight loss versus placebo, but all trials were of poor methodological quality [151]. A separate trial claiming benefits was strongly criticized by the FTC for critical flaws in design; two of three study authors subsequently retracted the publication [153-155].

Several small, short-term studies show modest weight loss (about 2 lbs per month more than placebo), and levels of chlorogenic acids in products may be important.

Safety: Generally well tolerated. Adverse effects: headaches and urinary tract infections [151]. Contains caffeine. Long-term safety not established. May affect blood pressure and blood sugar levels.

Beta-Glucans

Soluble fibers from oats, barley, yeast, and fungi that increase satiety and slow glucose absorption [16][22].

Clinical evidence:

An RCT of 66 women with overweight on a low-calorie diet found that 5-9 g/day beta-glucan from oat bran for 3 months did not produce greater weight loss than the control group [23]. All groups lost weight and had smaller waist circumference, but there were no significant between-group differences. Other trials of 3-10 g/day for 4-12 weeks similarly found no significant effect on weight loss [16].

Safety: Well tolerated. Increased flatulence reported, but no changes in stool consistency or bloating [24].

Vitamin C

Small studies suggest vitamin C supplementation may help with weight loss in significantly overweight individuals, but more research is needed. Vitamin C is safe, though high doses (1,000 mg) may cause diarrhea.

Stimulant Laxatives (Aloe, Senna, Cascara)

Products containing stimulant laxatives may cause temporary weight loss through water loss, but are not effective for sustained weight loss. By the time laxatives act in the large intestine, most nutrients and calories have already been absorbed in the small intestine.

Safety: Chronic use can cause dehydration, electrolyte imbalance, kidney failure, and death. The State of California requires warning labels on these products.

Diuretics (Dandelion, Asparagus, Uva Ursi)

Herbal diuretics may cause temporary water-weight loss but are not effective for fat loss. Well-controlled studies have not confirmed the diuretic effects of dandelion or asparagus. Most are considered non-toxic, but they may interact with medications and cause electrolyte loss.

Ephedra (Ma Huang) -- Banned Ingredient

Ephedra contains the alkaloids ephedrine, pseudoephedrine, norephedrine, and norpseudoephedrine [226-228]. In the 1990s, ephedra -- frequently combined with caffeine -- was popular in weight-loss supplements.

Historical clinical evidence: A meta-analysis of 20 clinical trials concluded that ephedrine and ephedra are modestly effective for short-term weight loss (6 months or less) [232]. Ephedrine stimulates the central nervous system, may increase thermogenesis, and acts as an appetite suppressant [229-231].

Safety and ban: Use was associated with nausea, vomiting, psychiatric symptoms (anxiety, mood change), hypertension, palpitations, stroke, seizures, heart attack, and death [232][233]. FDA banned the sale of dietary supplements containing ephedrine alkaloids in 2004 [234]. This ban remains in effect.

Acacia rigidula and BMPEA Contamination

Supplements listed as containing the plant extract Acacia rigidula have been found to contain beta-methylphenylethylamine (BMPEA), an amphetamine-like compound not approved for human use [Cohen, Drug Test Analysis 2015]. Animal studies suggest BMPEA could raise blood pressure and have effects similar to amphetamine-like substances. Multiple branded weight-loss products were identified as containing BMPEA.

Deterenol and Other Undeclared Stimulants

Deterenol (also called isopropylnorsynephrine) is a stimulant found in some weight-loss supplements that is not approved for human use in the U.S. It may be listed under names including isopropylnorsynephrine HCl, N-isopropylnorsynephrine HCl, and isopropyloctopamine. In human studies, doses of 2-5 mg/kg cause effects including flushing, anxiety, decreased diastolic blood pressure, and increased heart rate. At 5 mg/kg, it can cause inability to sit up, blurred vision, palpitations, weakness, and respiratory distress [Cohen, Clin Toxicol 2021]. An analysis of 17 brands found deterenol in doses up to 17 mg per serving and 69 mg per day.

Summary of Evidence

Ingredient	Weight Loss Effect	Quality of Evidence	Key Safety Concerns
Caffeine	Modest, short-term	Moderate (combination products)	Anxiety, insomnia, tachycardia at high doses
Green tea/EGCG	~1 kg over 12 weeks (with caffeine)	Moderate (Cochrane Review)	Liver damage (extract form)
Garcinia cambogia (HCA)	~0.88 kg over 2-12 weeks	Low (rigorous trials negative)	Rare mania, liver toxicity
Chromium	~0.5-1.1 kg	Low (Cochrane Review)	Generally safe at recommended doses
CLA	~0.7 kg over 6-12 months	Moderate	May worsen lipid profiles, insulin resistance
Bitter orange/synephrine	Inconclusive	Low	Cardiovascular events reported
L-Carnitine	~1.33 kg	Low-Moderate	TMAO increase; generally safe
Glucomannan	~0.79 kg (older analysis); recent reviews negative	Mixed	Esophageal obstruction (tablets)
Chitosan	~1.7 kg (low-quality studies)	Low	Shellfish allergy; warfarin interaction
Forskolin	No weight loss; may reduce body fat	Low (2 small trials)	May lower BP; hepatotoxicity in animal extract
White kidney bean	~1.86 kg fat loss (variable)	Low-Moderate	Mild GI effects
Probiotics	~0.54-0.6 kg	Low-Moderate	Generally safe
7-Keto DHEA	Additional weight loss with calorie restriction	Low (short-term only)	Not well studied
African mango	Possibly modest benefit	Low (single research group)	Renal failure in CKD patient
Raspberry ketone	No human data for ingredient alone	Very Low	Unknown at supplement doses
Calcium	No effect	High (multiple meta-analyses)	Kidney stones at high supplement doses
Vitamin D	No effect	Moderate	Toxic at very high doses
Capsaicin	Reduces calorie intake, not weight	Moderate	GI distress
Pyruvate	~0.72 kg	Low	GI effects; may worsen lipids
Hoodia	No effect	Very Low	BP and HR increases; liver concerns
Yohimbe	Inconclusive	Very Low	Potentially dangerous; deaths reported
Guar gum	No effect	Moderate (meta-analysis)	GI obstruction risk
Green coffee bean	~2.47 kg (poor-quality trials)	Very Low	Contains caffeine
Beta-glucans	No effect	Moderate	Well tolerated
Ephedra	Modest short-term effect	Moderate	BANNED -- stroke, heart attack, death

Recommended Dosing

Dosing recommendations apply only where sufficient evidence exists. For most weight-loss supplement ingredients, effective doses remain uncertain due to limited and heterogeneous research.

Ingredient	Studied Dose Range	Notes
Caffeine	100-400 mg/day	Do not exceed 400 mg/day total from all sources. Start low, assess tolerance. 200 mg/day limit during pregnancy.
Green tea catechins	270-690 mg EGCG/day (with caffeine)	Take with food to reduce liver risk. Avoid on empty stomach.
Garcinia cambogia (HCA)	500 mg HCA, 3-4 times daily	30-60 min before meals. Evidence of efficacy is weak.
Chromium picolinate	200-1,000 mcg/day	Effects on weight are minimal. Keep to 200 mcg/day for safety.
CLA	2.4-6 g/day	50:50 mixture of c9,t11 and t10,c12 isomers. Effects small.
Bitter orange (synephrine)	Up to 50 mg/day synephrine (alone)	40 mg/day max with up to 320 mg/day caffeine (Canada limits).
L-Carnitine	1.8-4 g/day	May require months for modest effects.
Glucomannan	1 g before each meal (3 g/day)	Must be taken with ample water.
Chitosan	2-3 g/day	Divide between largest meals.
Forskolin	250 mg extract (10% forskolin) twice daily	Use standardized Coleus forskohlii extract.
White kidney bean	445-3,000 mg/day	Before carbohydrate-rich meals. Look for AAIU standardization.
7-Keto DHEA	100 mg twice daily	Only studied short-term with calorie restriction + exercise.
Pyruvate	5-30 g/day	Large doses needed; GI effects common above 5 g.

Safety and Side Effects

General Principles

Most weight-loss supplement ingredients have only been studied short-term (4-16 weeks), so long-term safety data are largely absent. The most common adverse effects across ingredients are gastrointestinal: nausea, bloating, diarrhea, constipation, and abdominal discomfort.

For ingredients lacking convincing evidence of effectiveness, "even minor adverse events shift the delicate risk-benefits balance against their use" (Pittler and Ernst, 2004) [6].

Serious Safety Concerns

Several weight-loss ingredients carry risks of serious harm:

• Stimulants (caffeine, synephrine, ephedrine, yohimbine, BMPEA, deterenol): Cardiovascular events including hypertension, tachycardia, arrhythmias, stroke, myocardial infarction, and death. Risk is highest with high doses, multiple stimulants combined, or use in individuals with cardiovascular disease [42][43][218][232].
• Green tea extract: Liver damage, with at least 50 case reports since 2006. Risk may be higher with ethanolic extracts taken on an empty stomach [170][172][173].
• Garcinia cambogia: Rare liver toxicity (10 reported cases including 1 death and 2 transplants) and mania [134-137].
• Yohimbe: Potentially lethal. Associated with myocardial infarction, cardiac failure, and death at higher doses. 1,818 poison control reports in 12 years [222][223].
• Stimulant laxatives: Chronic abuse can cause dehydration, electrolyte imbalance, kidney failure, and death.
• Ephedra: BANNED since 2004 due to stroke, heart attack, and death [234].

Product Adulteration

Weight-loss supplements are among the most commonly adulterated dietary supplement categories. Between 2004 and 2012, 27% of Class I FDA recalls involved weight-loss products [238]. Common adulterants include:

• Sibutramine -- a withdrawn weight-loss drug (in 2016, FDA issued 36 public notifications about tainted weight-loss products containing sibutramine) [237]
• BMPEA -- an amphetamine-like compound found in Acacia rigidula products
• Deterenol -- an unapproved stimulant found in fat-burning supplements
• Other undeclared pharmaceutical ingredients

Consumers should be wary of products with claims that sound too good to be true, such as "lose weight without dieting or exercising" [235][236]. A product represented as a dietary supplement that contains drug ingredients is considered an unapproved drug subject to FDA enforcement [237].

Populations at Higher Risk

• Cardiovascular disease: Stimulant-containing supplements (caffeine, synephrine, yohimbe) should be avoided or used only under medical supervision.
• Diabetes: Some ingredients (glucomannan, chromium) may affect blood sugar; monitor closely and adjust medications if necessary.
• Liver disease: Avoid green tea extract, Garcinia cambogia, and yohimbe.
• Kidney disease: African mango was associated with renal failure in a patient with CKD [21].
• Pregnancy/breastfeeding: Most weight-loss supplements have not been studied in these populations and should be avoided. Caffeine should be limited to 200 mg/day during pregnancy [52].
• Children and adolescents: Weight-loss supplements are not recommended. The American Academy of Pediatrics discourages caffeine consumption in this age group [54].

Drug Interactions

Weight-loss supplement ingredients can interact with numerous medications:

Ingredient	Interacting Drugs	Mechanism/Effect
Caffeine/stimulant blends	Other stimulants, decongestants, MAOIs	Additive cardiovascular stimulation; increased BP and HR
Bitter orange/synephrine	Caffeine, decongestants, CYP3A4 substrates (cyclosporine, saquinavir)	Additive stimulant effects; inhibits CYP3A4 increasing drug levels [43]
Glucomannan	Oral medications (general), diabetes drugs	Decreases absorption of many oral drugs; may lower blood glucose [139][147]
Guar gum	Oral medications (general)	Decreases absorption of many oral drugs [147][179]
Chitosan	Warfarin	May potentiate anticoagulant effects [239]
Green tea	Chemotherapy agents, nadolol	Interferes with absorption and metabolism [240][241]
Garcinia cambogia	SSRIs	Associated with serotonin toxicity in combination [242]
Forskolin	BP medications, warfarin, clopidogrel, calcium channel blockers, nitroglycerin	May lower BP or increase HR; additive effects
Chromium	Insulin, metformin, sulfonylureas	May enhance blood sugar-lowering effects
Yohimbe	MAOIs, TCAs, antihypertensives	Hyperadrenergic effects; may cause hypertensive crisis with MAOIs

Fiber-containing supplements (glucomannan, guar gum, chitosan, psyllium) should be separated from medications by at least 2 hours to avoid reducing drug absorption. Individuals taking any medication should discuss weight-loss supplement use with their healthcare provider.

Dietary and Lifestyle Approaches

The evidence is clear that dietary supplements alone are insufficient for meaningful, sustained weight loss. Health experts consistently recommend a comprehensive approach [4-7]:

• Healthy dietary pattern: The 2020-2025 Dietary Guidelines for Americans recommends a pattern including vegetables, fruits, whole grains, lean proteins, and healthy fats while limiting added sugars, saturated fat, sodium, and alcohol.
• Caloric restriction: A modest calorie reduction (500-750 kcal/day below needs) is the foundation of weight-loss programs.
• Regular physical activity: Both aerobic exercise and resistance training support weight loss and, critically, weight-loss maintenance.
• Medical options: For individuals with a high BMI and additional health risks, physicians may prescribe FDA-approved medications (e.g., GLP-1 receptor agonists, orlistat) or recommend bariatric surgery in addition to lifestyle modifications [7].
• Calcium from dairy foods: Higher calcium from dairy products (but not supplements) is associated with greater weight loss during dieting, possibly due to additional bioactive components [60][61][64-67].
• Green tea as a beverage: Modest metabolic benefits from regular consumption without the liver risks associated with concentrated extracts.

None of the dietary supplement ingredients reviewed here produce weight loss comparable to these established approaches. Even the most promising ingredients (caffeine, green tea catechins with caffeine) produce effects of approximately 1-2 kg over 12 weeks, and these effects may diminish with tolerance.

References

[1] Flegal KM, Carroll MD, Kit BK, Ogden CL. "Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010." JAMA. 2012;307:491-7. PubMed

[2] Ogden CL, Carroll MD, Kit BK, Flegal KM. "Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010." JAMA. 2012;307:483-90. PubMed

[3] Lenz TL, Hamilton WR. "Supplemental products used for weight loss." J Am Pharm Assoc. 2004;44:59-67. PubMed

[4] U.S. Department of Agriculture, U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC.

[5] National Institute of Diabetes and Digestive and Kidney Diseases. "Keep Active and Eat Healthy to Improve Well-being and Feel Great." 2018.

[6] Pittler MH, Ernst E. "Dietary supplements for body-weight reduction: a systematic review." Am J Clin Nutr. 2004;79:529-36. PubMed

[7] Jensen MD, Ryan DH, Apovian CM, et al. "2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults." Circulation. 2014;129:S102-38. PubMed

[8] Blanck HM, Serdula MK, Gillespie C, et al. "Use of nonprescription dietary supplements for weight loss is common among Americans." J Am Diet Assoc. 2007;107:441-7. PubMed

[9] "A race of results." Nutr Bus J. 2016;21:1, 3-7.

[10] Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT. "Why US adults use dietary supplements." JAMA Intern Med. 2013;173:355-61. PubMed

[11] Sharpe PA, Granner ML, Conway JM, Ainsworth BE, Dobre M. "Availability of weight-loss supplements: Results of an audit of retail outlets in a southeastern city." J Am Diet Assoc. 2006;106:2045-51. PubMed

[12] U.S. General Accounting Office. "Dietary Supplements for Weight Loss: Limited Federal Oversight Has Focused More on Marketing than on Safety." 2002.

[13] U.S. Food and Drug Administration. "Questions and Answers on Dietary Supplements." 2019.

[14] Astell KJ, Mathai ML, Su XQ. "Plant extracts with appetite suppressing properties for body weight control: a systematic review." Complement Ther Med. 2013;21:407-16. PubMed

[15] Allison DB, Fontaine KR, Heshka S, et al. "Alternative treatments for weight loss: a critical review." Crit Rev Food Sci Nutr. 2001;41:1-28. PubMed

[16] Rios-Hoyo A, Gutierrez-Salmean G. "New dietary supplements for obesity: what we currently know." Curr Obes Rep. 2016;5:262-70. PubMed

[17] Egras AM, Hamilton WR, Lenz TL, Monaghan MS. "An evidence-based review of fat modifying supplemental weight loss products." J Obes. 2011;2011. PubMed

[18] Ngondi JL, Etoundi BC, Nyangono CB, et al. "IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight." Lipids Health Dis. 2009;8:7. PubMed

[19] Onakpoya I, Davies L, Posadzki P, Ernst E. "The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review." J Diet Suppl. 2013;10:29-38. PubMed

[20] Kothari SC, Shivarudraiah P, et al. "Subchronic toxicity and mutagenicity/genotoxicity studies of Irvingia gabonensis extract (IGOB131)." Food Chem Toxicol. 2012;50:1468-79. PubMed

[21] Ozkan G, Ulusoy S. "A case of renal failure developing in association with African mango consumption." Int J Clin Exp Med. 2015;8:6374-8. PubMed

[22] Aoe S, Ikenaga T, et al. "Effect of cooked white rice with high beta-glucan barley on appetite and energy intake." Plant Foods Hum Nutr. 2014;69:325-30. PubMed

[23] Beck EJ, Tapsell LC, et al. "Oat beta-glucan supplementation does not enhance the effectiveness of an energy-restricted diet in overweight women." Br J Nutr. 2010;103:1212-22. PubMed

[24] Queenan KM, Stewart ML, et al. "Concentrated oat beta-glucan lowers serum cholesterol in hypercholesterolemic adults." Nutr J. 2007;6:6. PubMed

[25] Haaz S, Fontaine KR, et al. "Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update." Obes Rev. 2006;7:79-88. PubMed

[26] Seifert JG, et al. "Effect of acute administration of an herbal preparation on blood pressure and heart rate." Int J Med Sci. 2011;8:192-7. PubMed

[27] Stohs SJ, Preuss HG, Shara M. "The safety of Citrus aurantium and its primary protoalkaloid p-synephrine." Phytother Res. 2011;25:1421-8. PubMed

[28] Roman MC, Betz JM, Hildreth J. "Determination of synephrine in bitter orange." J AOAC Int. 2007;90:68-81. PubMed

[29] Dwyer JT, Allison DB, Coates PM. "Dietary supplements in weight reduction." J Am Diet Assoc. 2005;105:S80-6. PubMed

[30] Stohs SJ, Preuss HG, Shara M. "A review of the human clinical studies involving Citrus aurantium extract." Int J Med Sci. 2012;9:527-38. PubMed

[31] Colker CM, Kaiman DS, et al. "Effects of Citrus aurantium extract, caffeine, and St. John's Wort on body fat loss." Curr Ther Res. 1999;60:145-53.

[32] Bent S, Padula A, Neuhaus J. "Safety and efficacy of Citrus aurantium for weight loss." Am J Cardiol. 2004;94:1359-61. PubMed

[33] Greenway F, et al. "Dietary herbal supplements with phenylephrine for weight loss." J Med Food. 2006;9:572-8. PubMed

[34] Onakpoya I, Davies L, Ernst E. "Efficacy of herbal supplements containing Citrus aurantium and synephrine." Focus Altern Complement Ther. 2011;16:254-60.

[35] Stohs SJ. "Assessment of the adverse event reports associated with Citrus aurantium." J Funct Foods. 2010;2:235-8.

[36] Kaats GR, Miller H, Preuss HG, Stohs SJ. "A 60-day safety study involving Citrus aurantium extract." Food Chem Toxicol. 2013;55:358-62. PubMed

[37] Haller CA, Benowitz NL, Jacob P 3rd. "Hemodynamic effects of ephedra-free weight-loss supplements." Am J Med. 2005;118:998-1003. PubMed

[38] Bui LT, Nguyen DT, Ambrose PJ. "Blood pressure and heart rate effects following a single dose of bitter orange." Ann Pharmacother. 2006;40:53-7. PubMed

[39] Hansen DK, et al. "Physiological effects following administration of Citrus aurantium for 28 days in rats." Toxicol Appl Pharmacol. 2012;261:236-47. PubMed

[40] Jung YP, et al. "Effects of a pre-workout supplement with and without synephrine for 8 weeks in resistance-trained males." J Int Soc Sports Nutr. 2017;14:1. PubMed

[41] Manore MM. "Dietary supplements for improving body composition and reducing body weight." Int J Sport Nutr Exerc Metab. 2012;22:139-54. PubMed

[42] Yen M, Ewald MB. "Toxicity of weight loss agents." J Med Toxicol. 2012;8:145-52. PubMed

[43] American Herbal Products Association. Botanical Safety Handbook. 2nd ed. Boca Raton, FL: CRC Press; 2013.

[44] Harpaz E, et al. "The effect of caffeine on energy balance." J Basic Clin Physiol Pharmacol. 2017;28:1-10. PubMed

[45] Astrup A, et al. "Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects." Am J Clin Nutr. 1990;51:759-67. PubMed

[46] Boozer CN, et al. "Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial." Int J Obes Relat Metab Disord. 2002;26:593-604. PubMed

[47] Ohara T, et al. "Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect." Nutr J. 2016;15:6. PubMed

[48] Andersen T, Fogh J. "Weight loss and delayed gastric emptying following a South American herbal preparation." J Hum Nutr Diet. 2001;14:243-50. PubMed

[49] Lopez-Garcia E, et al. "Changes in caffeine intake and long-term weight change in men and women." Am J Clin Nutr. 2006;83:674-80. PubMed

[50] Icken D, et al. "Caffeine intake is related to successful weight loss maintenance." Eur J Clin Nutr. 2016;70:532-4. PubMed

[51] U.S. Food and Drug Administration. "Spilling the Beans: How Much Caffeine is Too Much?" 2018.

[52] EFSA Panel on Dietetic Products, Nutrition and Allergies. "Scientific opinion on the safety of caffeine." EFSA Journal. 2015;13:4102-222.

[53] Torpy JM, Livingston EH. "JAMA patient page. Energy drinks." JAMA. 2013;309:297. PubMed

[54] Committee on Nutrition and the Council on Sports Medicine and Fitness. "Sports drinks and energy drinks for children and adolescents." Pediatrics. 2011;127:1182-9. PubMed

[55] Haller C, et al. "Dietary supplement adverse events: report of a one-year poison center surveillance project." J Med Toxicol. 2008;4:84-92. PubMed

[56] Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, IOM. Dietary Reference Intakes for Calcium and Vitamin D. 2011. PubMed

[57-67] Calcium, dairy, and body weight studies (Davies 2000, Heaney 2003, Parikh 2003, Zemel 2000, Villarroel 2014, Christensen 2009, Jacobsen 2005, Heaney 2002, and others).

[68-77] Calcium supplementation trials and kidney stone risk studies.

[78] Whiting S, Derbyshire E, Tiwari BK. "Capsaicinoids and capsinoids: a potential role for weight management?" Appetite. 2012;59:341-8.

[79-83] Capsaicinoid mechanism and efficacy studies (Urbina 2017 and others).

[84-91] Carnitine reviews, meta-analyses, and TMAO studies.

[92-97] Chitosan trials and Cochrane Review (Gades 2003, Pittler 2003, Jull 2008, and others).

[98] Institute of Medicine. Dietary Reference Intakes for Chromium. 2001.

[99] Onakpoya I, Posadzki P, Ernst E. "Chromium supplementation in overweight and obesity: a systematic review and meta-analysis." Obes Rev. 2013;14:496-507.

[100] Tian H, et al. "Chromium picolinate supplementation for overweight or obese adults." Cochrane Database Syst Rev. 2013;(11):CD010063.

[101-102] Additional chromium studies.

[103-108] Forskolin studies (Godard, Obes Res 2005; Henderson, J Int Soc Sports Nutr 2005; and others).

[109] Gaullier JM, et al. "Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans." Am J Clin Nutr. 2004;79:1118-25.

[110-124] CLA studies, safety data, and lipid effects.

[125-127] Fucoxanthin studies (Abidov, Diabetes Obes Metab 2010).

[128-137] Garcinia cambogia trials, reviews, and safety reports (Onakpoya, J Obes 2011; Heymsfield, JAMA 1998; Semwal, Fitoterapia 2015).

[138-147] Glucomannan studies and safety data.

[148-155] Green coffee bean extract studies, meta-analysis, and FTC criticism.

[156-173] Green tea studies, Cochrane Review, EFSA opinion, and liver toxicity reports.

[157] Hursel R, et al. "The effects of catechin rich teas and caffeine on energy expenditure and fat oxidation: a meta-analysis." Obes Rev. 2011;12:e573-81.

[164] Jurgens TM, et al. "Green tea for weight loss and weight maintenance in overweight or obese adults." Cochrane Database Syst Rev. 2012;12:CD008650.

[165] Phung OJ, et al. "Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis." Am J Clin Nutr. 2010;91:73-81.

[167] Hursel R, Viechtbauer W, Westerterp-Plantenga MS. "The effects of green tea on weight loss and weight maintenance: a meta-analysis." Int J Obes. 2009;33:956-61.

[170] Dostal AM, et al. "Green tea extract and catechol-O-methyltransferase genotype modify the post-prandial thermogenic effect of green tea." J Nutr. 2016.

[174] Pittler MH, Ernst E. "Guar gum for body weight reduction: meta-analysis of randomized trials." Am J Med. 2001;110:724-30.

[175-179] Guar gum studies and safety data.

[180-186] Hoodia studies and product quality analyses.

[187-199] Probiotic studies and safety data (Kadooka 2010, Sanchez 2014, and meta-analyses).

[200-203] Pyruvate clinical trials.

[204-206] Raspberry ketone studies.

[207-210] Vitamin D and body weight studies.

[211] Onakpoya I, et al. "The efficacy of Phaseolus vulgaris as a weight-loss supplement: a systematic review." Br J Nutr. 2011;106:196-202.

[212-217] White kidney bean extract trials.

[218-225] Yohimbe studies and safety data (Pittler, Cochrane 2003; and others).

[226-234] Ephedra studies, meta-analysis, and FDA ban (Shekelle, JAMA 2003; FDA 2004).

[235-236] FDA and FTC warnings on fraudulent weight-loss claims.

[237] FDA. "Tainted Weight Loss Products." Public database.

[238] Harel Z, et al. "The frequency and characteristics of dietary supplement recalls in the United States." JAMA Intern Med. 2013;173:929-30.

[239] Chitosan-warfarin interaction data.

[240-241] Green tea-chemotherapy interaction studies.

[242] Lopez AM, et al. "Serotonin toxicity associated with Garcinia cambogia." Case report.

ConsumerLab. "Weight Loss Supplements Review." https://www.consumerlab.com/reviews/weight-loss-supplements-7-keto-dhea/weightloss/

NIH Office of Dietary Supplements. "Dietary Supplements for Weight Loss -- Health Professional Fact Sheet." https://ods.od.nih.gov/factsheets/WeightLoss-HealthProfessional/